Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline

Full text
Author(s):
Xavier Tomaz, Paulo Roberto [1] ; Kajita, Mariana Soares [2] ; Santos, Juliana Rocha [1] ; Scholz, Jaqueline [3] ; Abe, Tania Ogawa [3] ; Gaya, Patricia Viviane [3] ; Krieger, Jose Eduardo [1] ; Pereira, Alexandre Costa [1] ; Junior Lima Santos, Paulo Caleb [2]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Inst Coracao InCor, Hosp Clin HCFMUSP, Fac Med, Lab Genet & Mol Cardiol, Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Unifesp, EPM, Dept Pharmacol, Sao Paulo - Brazil
[3] Univ Sao Paulo, Inst Coracao InCor, Hosp Clin HCFMUSP, Fac Med, Smoking Cessat Program Dept, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY; v. 75, n. 11, p. 1541-1545, NOV 2019.
Web of Science Citations: 0
Abstract

Background The identification of variants in genes involved in nicotine metabolism may have implications for the pharmacological therapy of smoking. In the scenario of precision medicine, the aim of this study was to evaluate a possible association of cytochrome P450 2A6 and 2B6 polymorphisms with varenicline pharmacotherapy. Methods The present study included 167 patients treated with varenicline in monotherapy who were from a cohort study of 1049 patients (treated with smoking cessation drugs: nicotine replacement therapy, bupropion, varenicline, or combinations of same). Smoking cessation success was considered for patients who completed 6 months of continuous abstinence. The CYP2A6 rs1801272 and rs28399433 and CYP2B6 rs8109525 polymorphisms were genotyped by real-time PCR using the TaqMan (R) platform. Results Patients with AG or GG genotypes for CYP2B6 rs8109525 had a higher success rate of smoking cessation with varenicline (51.2%) compared with carriers of the AA genotypes (33.3%, P = 0.03, n = 167). The AG or GG genotypes were also associated with a higher odds ratio of success, even in a multivariate analysis adjusting for potential confounders (OR = 2.01; 95%CI = 1.01 to 4.00; P = 0.047). Conclusion CYP2B6 rs8109525 was associated with a higher success rate of smoking cessation with varenicline treatment. This finding may be useful in pharmacogenomic strategies for smoking cessation therapy. (AU)

FAPESP's process: 13/09295-3 - Pharmacogenetic of cardiovascular system drugs focusing on implementation
Grantee:Paulo Caleb Júnior de Lima Santos
Support Opportunities: Research Grants - Young Investigators Grants